TWIST BIOSCIENCE CORP
TWSTNASDAQTrading Snapshot
- Day Range
- $183.35 – $188.31
- 52-Week Range
- $23.30 – $186.20
- Volume
- $6.77B
- Avg Volume
- $5.45B
- Shares Outstanding
- 62.3M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $377M
- Last Q Revenue
- $118M
- P/E Ratio
- -82.4
- P/S Ratio
- 26.4x
- EPS (TTM)
- $-2.19
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.2%
Why Investors Own TWST
- ✓High-growth profile — revenue up +12.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TWIST BIOSCIENCE CORP
TWST
StockOtter · stockotter.spaceAbout TWIST BIOSCIENCE CORP
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.
3 Analysts, 3 Trades to Make Today
Louis says buy the AI dip
Why Twist Bioscience Stock Skyrocketed This Week
The biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collabo
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching